Projekty B+R
1. Development of methods of non-invasive genetic diagnostics and cancer prevention – liquid biopsy
Project co-financed from the European Union funds under the European Regional Development Fund (ERDF), carried out within Regional Operational Programme of the Mazowieckie Voivodeship 2014-2020, Priority axis 1 Use of research and development activity in economy, Measure 1.2 R&D activity of enterprises, project type: Research and development projects
Project title: Development of methods of non-invasive genetic diagnostics and cancer prevention - liquid biopsy
Grant Agreement No. RPMA.01.02.00-14-6209/16-00 dated on 11.04.2017 r.
Name of the beneficiary: Genomed SA
Value of the project: 3,206,751.46 PLN
Amount of co-financing: 2,071,253.46 PLN
Duration of the project: 01.10.2016 - 31.12.2018
The aim of the project:
Development of non-invasive genetic diagnostics and cancer prevention methods, based on the liquid biopsy - analysis of an innovative biomarker, tumor cell-free DNA, using the new generation sequencing technology (NGS).
As a result of the project:
- A diagnostic (NGS) panel for oncology patients was developed, based both on cell-free DNA (cfDNA) and DNA derived from cancer tissues.
- The possibility of using a biomarker, which is circulating tumor DNA, for cancer monitoring has been confirmed.
- The methodology of analysing a potential risk of developing civilisation diseases, with particular attention to cancer diseases, based on whole-genome sequencing, has been developed.
- A web-based platform, that allows online access of an expert, doctor and patient, has been created: www.plynnabiopsja.eu
2. Innovative strategy for diagnostics, prevention and adiuvant therapy of selected neurodegenerative disorders in population of Polish ancestry
The project is co-financed by the National Centre for Research and Development (NCBiR), within the strategic programme: STRATEGMED „Prevention practices and treatment of civilization diseases””
Project title: Innovative strategy for diagnostics, prevention and adiuvant therapy of selected neurodegenerative disorders in population of Polish ancestry
Name of the beneficiary: Consortium NeuStemGen
The consortium:
1. Pomeranian Medical University in Szczecin (applicant and leader)
2. Medical University of Silesia in Katowice
3. Genomed SA
4. Mossakowski Medical Research Centre Polish Academy of Sciences
5. Polish-Japanese Academy of Information Technology
6. The West Pomeranian University of Technology in Szczecin
7. University of Warmia and Mazury in Olsztyn
8. Foundation Ewa Blaszczyk "Akogo" public benefit organization
Value of the project: 20.4 million PLN
Duration of the project: 01.09.2014 - 31.12.2017
Project description:
The aim of the project: development and implementation of innovative diagnostic methods concerning diseases of retinal degeneration, including age-related macular degeneration (AMD), in routine medical practice. Developing innovative methods of isolation, expansion, modification, differentiation and increase of the regenerative potential of myeloid stem cells in clinical practice. As a result, the project will lead to the development of innovative treatment methods based on the use of stem cells in neurology and ophthalmology.
3. Polish Reference Genome for Genomic Diagnostics and Personalised Medicine
The project co-financed by the National Centre for Research and Development (NCBiR), within the INNOTECH programme, In-Tech programme path
Project title: Polish Reference Genome for Genomic Diagnostics and Personalised Medicine
Name of the beneficiary: Consortium POLGENOM – Genomed SA (a leader)
Value of the project: 5,984,717.00 PLN
Duration of the project: 01.01.2013 - 29.02.2016
Project description:
The project assumption was a close cooperation of the Company with the best institutes in Poland in the field of molecular biology and medicine. The main achievement of this project is the reference database of the Polish Caucasian subpopulation for the commercial use in diagnostic processes and in research in the field of personalised medicine. The Polish Reference Genome Database collects genetic variants specific for a healthy, long-lived individual. It is based on the whole genome sequences of 126 healthy, long-lived (90+) Poles and contains a wide range of clinical and biochemical data. The database has been implemented for the practical use in diagnostic laboratories and in pharmaceutical companies, while introducing new drugs, which action is dependent on the genotype of the patient. The obtained set of data shall serve as a control group for all population-based genetic studies on different groups of patients and will be a great support in clinical research as well as applied studies of Polish and foreign scientific institutions.
4. Application of Molecular Diagnostics in the Development of Personalised Medicine
Investing in Your future - Grants for innovation
Project co-financed from the European Union funds under the European Regional Development Fund, The Innovative Economy Operational Programme
Measure 1.4 Support for goal-oriented projects under Priority 1 Research and development of modern technologies
Project title: Application of Molecular Diagnostics in the Development of Personalised Medicine
Name of the beneficiary: Genomed SA
Value of the project: 4,274,555.00 PLN
EU’s contribution: 69.80%
Duration of the project: 01.07.2012 - 30.09.2015
Project description:
The aim of the project was to develop innovative services for personalised medicine based on genome sequencing technology, used for high-throughput analysis of selected regions of patient’s genomes, including, among others, genes responsible for cancer and response to drugs. It is worth emphasizing that the developed product is tailored to the financial resources of the Polish state and its citizens.
5. Introducing innovative services of Genomed SA to the international market
Investing in Your future - Grants for innovation
Project co-financed from the European Union funds under the European Regional Development Fund, The Innovative Economy Operational Programme
Project title: Introducing innovative services of Genomed SA to the international market
Name of the beneficiary: Genomed SA
Value of the project: 869,611.00 PLN
Amount of co-financing: 530,850.00 PLN
Duration of the project: 11.04.2012 - 31.03.2015
Project description:
The aim of the project was to increase the export of services offered by Genomed, and to establish a cooperation with foreign partners. Within the project, Genomed participated in trade fairs in Europe, Asia and America, international economic missions and training sessions presenting various aspects of the expansion on the foreign markets.
6. Application of the Technology of Whole Human Genome Sequencing in Medical Diagnostics
Investing in Your future - Grants for innovation
Project co-financed from the European Union funds under the European Regional Development Fund, The Innovative Economy Operational Programme
Measure 1.4 Support for goal-oriented projects under Priority 1 Research and development of modern technologies
Measure 4.1 Support for implementation of results of R&D works under Priority IV Investments in innovative undertakings
Name of the beneficiary: Genomed Sp. z o.o. [Ltd.]
Value of the project: 4,496,836.16 PLN
EU’s contribution: 58.23%
Duration of the project: 20.10.2009 - 31.12.2013
